Latest Headlines

PR Newswire

Neeyamo reconnu leader et collaborateur d'exception dans l'évaluation PEAK Matrix® 2026 d'Everest Group pour les solutions de paie multi-pays

PR Newswire

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

PR Newswire

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology